BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Tuesday. The firm issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reiterated a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Price Performance

Shares of NASDAQ BIOL opened at $0.01 on Tuesday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The company’s 50-day moving average is $0.01 and its 200 day moving average is $0.04. The stock has a market capitalization of $293,981.60, a P/E ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.